PolyPid Clears Israeli Health Ministry GMP Inspection
Ticker: PYPD · Form: 6-K · Filed: Sep 16, 2025 · CIK: 1611842
| Field | Detail |
|---|---|
| Company | Polypid Ltd. (PYPD) |
| Form Type | 6-K |
| Filed Date | Sep 16, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, manufacturing, pharmaceuticals
TL;DR
PolyPid passed Israeli health inspection for D-PLEX100 manufacturing. Big step for commercialization.
AI Summary
PolyPid Ltd. announced on September 16, 2025, that it has successfully completed a Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health. This inspection is a critical step towards achieving commercial manufacturing readiness for their product, D-PLEX100.
Why It Matters
Successful GMP inspection is a key regulatory milestone, bringing PolyPid closer to commercializing its D-PLEX100 product and potentially impacting patient access to new treatments.
Risk Assessment
Risk Level: medium — While a positive development, the company's commercial manufacturing readiness and product success are still subject to further regulatory approvals and market acceptance.
Key Players & Entities
- PolyPid Ltd. (company) — Registrant
- Israeli Ministry of Health (company) — Regulatory body
- D-PLEX100 (product) — Product undergoing manufacturing readiness
- September 16, 2025 (date) — Date of press release and inspection completion
FAQ
What was the specific outcome of the Israeli Ministry of Health GMP inspection for PolyPid Ltd.?
PolyPid Ltd. successfully completed the GMP inspection by the Israeli Ministry of Health.
What product is this inspection related to?
The inspection is related to the commercial manufacturing readiness for D-PLEX100.
What is the significance of this GMP inspection for PolyPid?
It is a critical step towards achieving commercial manufacturing readiness for D-PLEX100.
When was the press release regarding this inspection issued?
The press release was issued on September 16, 2025.
What form is this filing?
This filing is a Form 6-K, a Report of Foreign Private Issuer.
Filing Stats: 315 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2025-09-16 08:36:44
Filing Documents
- ea0257530-6k_polypid.htm (6-K) — 16KB
- ea025753001ex99-1_polypid.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-25-087942.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. POLYPID LTD. Date: September 16, 2025 By: /s/ Dikla Czaczkes Akselbrad Name : Dikla Czaczkes Akselbrad Title: Chief Executive Officer 3